Tarsus Q2 FY26 net loss narrows 8.77% to $18.55 million; net product sales rise more than 69% to $173.91 million

Reuters2026/08/06 11:12

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Tarsus posted Q2 2026 net sales of USD 173.9 million, up more than 69% year over year.
Net loss narrowed to USD 18.6 million; loss per share improved to USD 0.43.
RD expenses climbed to USD 31 million; SGA rose to USD 150.7 million, driven by higher commercial and marketing costs.
Cash, cash equivalents and marketable securities totaled USD 449.7 million as of June 30, 2026.
Raised full-year 2026 XDEMVY net sales guidance to USD 685-705 million; agreed to acquire Alkeus Pharmaceuticals and its Phase 3 Stargardt candidate ALK-001.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tarsus Pharmaceuticals Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Tarsus Q2 FY26 net loss narrows 8.77% to $18.55 million; net product sales rise more than 69% to $173.91 million

You may also like

Crypto prices